Margetuximab
Margetuximab is a chimeric IgG monoclonal antibody against HER2 designed for the treatment of cancer.[1][2]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Chimeric (mouse/human) |
Target | HER2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
Chemical and physical data | |
Formula | C6484H10010N1726O2024S42 |
Molar mass | 145.9 kg/mol g·mol−1 |
This drug was created by Raven biotechnologies, which was later acquired by MacroGenics. It was engineered to increase affinity for CD16A polymorphisms and decrease affinity for FcγRIIB (CD32B), an inhibitory receptor.[3]
It binds to the same target (epitope) as trastuzumab,[4] on the HER2 receptor.
It is currently in phase 3 clinical trials for combination therapy in metastatic breast cancer[5] in collaboration with Merck.[6] Phase II trials are also in progress for gastric cancer and esophageal cancer.[7]
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Margetuximab, American Medical Association.
- https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=681010
- "Margetuximab". AdisInsight. Retrieved 1 February 2017.
- Pegram Discusses Promise of Margetuximab/Chemo Combo for HER2+ Breast Cancer. Jan 2017
- https://clinicaltrials.gov/ct2/show/NCT02492711
- http://www.mercknewsroom.com/news-release/prescription-medicine-news/macrogenics-and-merck-collaborate-immuno-oncology-study-eval
- https://clinicaltrials.gov/ct2/show/NCT02689284
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.